Phase 1 Study to Assess Safety and Efficacy of ANG003

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 25, 2023

Primary Completion Date

July 8, 2024

Study Completion Date

July 8, 2024

Conditions
Exocrine Pancreatic Insufficiency
Interventions
DRUG

ANG003

To evaluate four possible combinations of lipase, protease and amylase.

Trial Locations (20)

10595

New York Medical College at Westchester Medical Center, Valhalla

12208

Albany Medical College, Albany

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

40202

Norton Children's Research Institute affiliated with University of Louisville School of Medicine, Louisville

43205

Nationwide Children's Hospital, Columbus

44106

University Hospitals of Cleveland Medical Center, Cleveland

44308

Akron Childrens Hospital, Akron

45267

University of Cincinnati, Cincinnati

48109

University of Michigan Medical Center, Ann Arbor

48201

Harper University Hospital / Wayne State University, Detroit

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

72205

University of Arkansas for Medical Sciences, Little Rock

75235

University of Texas Southwestern Medical Center, Dallas

80206

National Jewish Health, Denver

84132

University of Utah, Salt Lake City

90806

Long Beach Memorial Medical Center, Long Beach

02114

Massachusetts General Hospital,, Boston

02115

Boston Children's Hospital, Boston

03756

Dartmouth Hitchcock Medical Center, Lebanon

Sponsors
All Listed Sponsors
lead

Anagram Therapeutics, Inc.

INDUSTRY

NCT06052293 - Phase 1 Study to Assess Safety and Efficacy of ANG003 | Biotech Hunter | Biotech Hunter